Ketamine for PTSD: What the Research Shows

If you're reading this, you've likely tried the standard treatments for PTSD, the SSRIs, the therapy sessions, maybe both, and you're still struggling. That's not uncommon. While evidence-based therapies like CPT, prolonged exposure, and EMDR work well for many people, a significant portion of PTSD patients don't achieve full remission with these approaches. That reality has driven clinical interest in ketamine as a potential option for PTSD that hasn't responded to first-line treatments.

This page covers what the research says, what we know, what we don't, and how to decide whether ketamine therapy might be worth discussing with a provider.

Key Facts

• FDA status: Ketamine is NOT FDA-approved for PTSD. All use for PTSD is off-label.
• Evidence level: Emerging. A landmark 2021 randomized controlled trial in JAMA Psychiatry (Feder et al.) showed significant improvement in PTSD symptoms with repeated ketamine infusions compared to an active control.
• Administration: IV or IM (intramuscular), in a monitored clinical setting
• Who it's for: Patients with PTSD who have not responded adequately to first-line treatments (therapy and/or medication)

How Ketamine Works for PTSD

Standard PTSD medications (SSRIs like sertraline and paroxetine) work by increasing serotonin availability. They're modestly effective: response rates for SSRIs in PTSD are around 60%, and remission rates are lower, typically 20-30%. For the 40-70% of patients who don't achieve remission, the pharmacological options narrow quickly.

Ketamine works through a fundamentally different pathway:

NMDA receptor modulation. Ketamine blocks NMDA glutamate receptors, which are involved in fear learning and memory consolidation, the core processes that maintain PTSD. By modulating these receptors, ketamine may help reduce the emotional intensity of traumatic memories.

Synaptic plasticity. Ketamine promotes the release of brain-derived neurotrophic factor (BDNF) and stimulates rapid growth of new synaptic connections in the prefrontal cortex. This neuroplasticity may help the brain form new associations that aren't dominated by the trauma response.

Rapid onset. Unlike SSRIs, which take weeks, ketamine's effects on mood and stress reactivity can begin within hours. This rapid action has clinical significance for patients in acute distress, though the duration of benefit varies and typically requires repeated sessions.

Potential for enhanced therapy response. Some researchers hypothesize that ketamine's window of increased neuroplasticity could make patients more responsive to concurrent psychotherapy. This "ketamine-assisted psychotherapy" model is being actively studied, though it is not yet standard of care.

What the Clinical Evidence Shows

The evidence for ketamine in PTSD is growing but still limited compared to its evidence base for depression. Here's what the most relevant studies show:

Feder et al., 2014 (proof of concept):

A randomized crossover trial published in JAMA Psychiatry found that a single IV ketamine infusion produced rapid reduction in PTSD symptoms compared to midazolam (active placebo) within 24 hours in patients with chronic PTSD. The effect was short-lived, suggesting repeated dosing would be needed.

Feder et al., 2021 (the landmark trial):

The same research team published a larger randomized controlled trial in The American Journal of Psychiatry. Patients with chronic PTSD received repeated IV ketamine infusions (3 per week for 2 weeks, 6 total) versus midazolam. Results showed that ketamine produced significantly greater improvement in PTSD symptom severity (measured by the CAPS-5) compared to the control group. The mean reduction in CAPS-5 score was clinically meaningful. Importantly, benefits diminished after the infusion series ended, suggesting that maintenance dosing and/or concurrent therapy may be needed to sustain improvement.

Abdallah et al., 2022:

A study in Chronic Stress examined repeated ketamine infusions in veterans with PTSD and found reductions in PTSD severity, depression, and sleep disturbance. Sample size was small, and larger trials were recommended.

What we don't yet know:

• Optimal dosing protocols for PTSD specifically (most clinics extrapolate from depression protocols)
• Long-term efficacy beyond the active treatment period
• Which PTSD subtypes respond best
• Whether ketamine-assisted psychotherapy produces better outcomes than ketamine alone
• Safety of long-term repeated dosing

This is an active area of research, and the evidence base is expected to grow significantly in the coming years.

Who Is a Candidate for Ketamine for PTSD

Ketamine for PTSD is not a first-line treatment. It's considered when standard approaches haven't worked.

You may be a candidate if:

• You have a confirmed PTSD diagnosis
• You've tried at least one first-line psychotherapy (CPT, PE, or EMDR) and at least one SSRI/SNRI without adequate response
• Your symptoms are significantly impairing your daily functioning
• You don't have a history of active psychosis or schizophrenia
• You don't have uncontrolled hypertension (ketamine can temporarily elevate blood pressure)
• You don't have active substance use disorder involving ketamine or similar substances

You are NOT a candidate if:

• You have active psychosis or a history of schizophrenia spectrum disorders
• You have uncontrolled high blood pressure or cardiovascular disease
• You have active substance abuse involving dissociative substances
• You are pregnant
• You haven't tried evidence-based first-line treatments yet

A thorough psychiatric evaluation determines candidacy. At Ascend, we don't offer ketamine to anyone who walks in requesting it. The evaluation comes first.

What to Expect During Ketamine Treatment for PTSD

Treatment follows a structured protocol:

Before treatment:

• Full psychiatric evaluation including PTSD severity assessment (CAPS-5 or PCL-5)
• Medical history and physical health screening
• Discussion of expectations, risks, and realistic outcomes
• Review of current medications

During a session:

• Sessions are conducted in a calm, monitored clinical environment
• Vital signs (blood pressure, heart rate, oxygen saturation) are monitored throughout
• The session lasts approximately 40-60 minutes for the infusion plus a monitoring period
• You may experience dissociation, changes in perception, dizziness, or nausea during the infusion. These effects are temporary and resolve within 1-2 hours.
• You cannot drive for the rest of the day after a session

Treatment course:

• An induction series typically involves 6 sessions over 2-3 weeks
• Response is evaluated after the induction series
• Maintenance sessions (frequency varies) may be recommended for patients who respond
• Ketamine is used alongside, not instead of, ongoing psychiatric care and/or therapy

Risks and Side Effects

Ketamine is a Schedule III controlled substance. It is not without risks.

Common side effects during infusion:

• Dissociation (feeling detached from your body or surroundings)
• Dizziness and lightheadedness
• Nausea (usually mild)
• Elevated blood pressure and heart rate (monitored throughout)
• Visual changes

Less common concerns:

• Bladder irritation with frequent, long-term use (more relevant to recreational abuse; less common at medical doses)
• Psychological dependence (low risk at medical doses under supervision, but nonzero)
• Cognitive effects with very frequent use

Side effects typically resolve within 1-2 hours after the session ends. Medical supervision during every session is non-negotiable.

How Ascend Approaches Ketamine for PTSD

At Ascend Mind and Body, ketamine therapy for PTSD is administered by Anna Stouffer, PMHNP-BC, under a protocol that prioritizes safety, proper screening, and realistic expectations.

We begin with a comprehensive psychiatric evaluation. If PTSD is confirmed and first-line treatments have been insufficient, we discuss ketamine as one option among several. We review the evidence honestly, including what it shows and what it doesn't.

For patients who proceed, we monitor clinical response using standardized PTSD measures throughout the treatment course. We also coordinate with your therapist (whether at Ascend or externally) to maximize the benefit of any neuroplasticity window ketamine may create.

We're transparent about what ketamine for PTSD can and cannot do. It's not a cure. It's not right for everyone. For the right patient, it may provide meaningful symptom relief that opens the door to more effective therapy. That's the clinical rationale.

For PTSD-specific background, see our comprehensive PTSD condition page.

Ketamine therapy is typically cash-pay. Psychiatric evaluations may be covered by insurance. Our providers are in-network with Aetna, Cigna, UnitedHealthcare, Medicare, Medicaid, TRICARE, AARP, and ChampVA. Visit our new patients page to schedule a consultation.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment.